Protara Therapeutics Q3 2026 Results: Net Loss of $21.7M, Loss Widens
Protara Therapeutics reported a net loss of $61.1 million for the nine months ended September 30, 2026, compared to a $40.1 million loss in the prior year, driven primarily by a significant increase in research and development expenses. As of September 30, 2026, the company maintained $127.1 million in cash, cash equivalents, and marketable debt securities to fund its clinical pipeline, including TARA-002 and IV Choline Chloride.
- Key figure
- Net loss $21.7M